|
|
|
|
The major obstacle to general acceptance of thrombolytic therapies and rTPA in particular is the fear of symptomatic hemorrhagic transformation, and because HMPAO-SPECT might reliably identify patients at high risk of symptomatic hemorrhagic transformation,the clinical value of HMPAO-SPECT in patient selection for thrombolysis during the first hours of acute ischemic stroke should be determined through a prospective clinical trial. |
|